Autoimmunity and cytokines: Pathogenesis and therapy

The Cytokine Handbook

Volumn , Issue , 2003, Pages 1189-1211

  Andreakos, Evangelos Th ^a   Feldmann, Marc ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 71249110784     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1016/B978-012689663-3/50056-9     Document Type: Chapter

References (229)

1. Akahoshi T., Wada C., Endo H., et al. Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Regulation of its production in synovial cells by interleukin-1 and tumor necrosis factor. Arthritis Rheum 1993, 36:762-771.
2. Almon R.R., Andrew C.G., Appel S.H. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science 1974, 186:55-57.
3. Alvaro-Gracia J.M., Zvaifler N.J., Firestein G.S. Cytokines in chronic inflammatory arthritis. IV. Grnaulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J. Exp. Med. 1989, 170:865-875.
4. Alvaro-Gracia J.M., Zvaifler N.J., Brown C.B., et al. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J. Immunol. 1991, 146:3365-3371.
5. Angel P., Imagawa M., Chiu R., et al. Phorbol esterinducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 1987, 49:729-739.
6. Anonymous Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:655-661.
7. Anonymous Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352:1498-1504.
8. Anonymous Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998, 352:1491-1497.
9. Asadullah K., Docke W.D., Ebeling M., et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch. Dermatol. 1999, 135:187-192.
10. Atkins M.B., Mier J.W., Parkinson D.R., et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N. Engl. J. Med. 1988, 318:1557-1563.
11. Autschbach F., Braunstein J., Helmke B., et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am. J. Pathol. 1998, 153:121-130.
12. Baert F.J., D’Haens G.R., Peeters M., et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999, 116:22-28.
13. Bahram S., Arnold D., Bresnahan M., et al. Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region. Proc. Natl Acad. Sci. USA 1991, 88:10094-10098.
14. Baker D., Steinmann L., Gijbels K. Cytokines in multiple sclerosis. Cytokines in Autoimmunity 1996, 77-100. R.G. Landes Company, London. F.M. Brennan, M. Feldmann (Eds.).
15. Baum H., Peakman M., Norazmi M.N., Vergani D. Molecular mimicry and the T-cell repertoire. Diabetologia 1996, 39:246-247.
16. Bell J.I., Denney D., Foster L., et al. Allelic variation in the DR subregion of the human major histocompatibility complex. Proc. Natl Acad. Sci. USA 1987, 84:6234-6238.
17. Benoist C., Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry?. Nat. Immunol. 2001, 2:797-801.
18. Beutler B. Autoimmunity and apoptosis: the Crohn’s connection. Immunity 2001, 15:5-14.
19. Bondeson J., Foxwell B., Brennan F., Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc. Natl Acad. Sci. USA 1999, 96:5668-5673.
20. Bondeson J., Browne K.A., Brennan F.M., et al. Selective regulation of cytokine induction by adenoviral gene transfer of IkappaBalpha into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-kappaB independent. J. Immunol. 1999, 162:2939-2945.
21. Borghaei R.C., Rawlings P.L., Mochan E. Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts. Arthritis Rheum. 1998, 41:1398-1406.
22. Bottazzo G.F., Pujol-Borrell R., Hanafusa T., Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine auto-immunity. Lancet 1983, 2:1115-1119.
23. Brandt J., Haibel H., Cornely D., et al. Successful treatment of active ankylosing spondylitis with the antitumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000, 43:1346-1352.
24. Cytokines in Autoimmunity 1996, R.G. Landes Company, London. F.M. Brennan, M. Feldmann (Eds.).
25. Brennan F.M., Chantry D., Jackson A.M., et al. Cytokine production in culture by cells isolated from the synovial membrane. J. Autoimmun 1989, 2(Suppl.):177-186.
26. Brennan F.M., Chantry D., Jackson A., et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989, 2:244-247.
27. Brennan F.M., Chantry D., Turner M., et al. Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures. Clin. Exp. Immunol. 1990, 81:278-285.
28. Brennan F.M., Zachariae C.O., Chantry D., et al. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur. J. Immunol. 1990, 20:2141-2144.
29. Bresnihan B., Alvaro-Gracia J.M., Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998, 41:2196-2204.
30. Bucala R., Ritchlin C., Winchester R., Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J. Exp. Med. 1991, 173:569-574.
31. Buchan G., Barrett K., Turner M., et al. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin. Exp. Immunol. 1988, 73:449-455.
32. Buchan G., Barrett K., Fujita T., et al. Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin. Exp. Immunol. 1988, 71:295-301.
33. Burman P., Totterman T.H., Oberg K., Karlsson F.A. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J. Clin. Endocrinol. Metab. 1986, 63:1086-1090.
34. Butler D.M., Maini R.N., Feldmann M., Brennan F.M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw. 1995, 6:225-230.
35. Buttice G., Quinones S., Kurkinen M. The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin, gene. Nucleic Acids Res. 1991, 19:3723-3731.
36. Calder E.A., Penhale W.J., McLeman D., et al. Lymphocyte-dependent antibody-mediated cytotoxicity in Hashimoto thyroiditis. Clin. Exp. Immunol. 1973, 14:153-158.
37. Chabaud M., Durand J.M., Buchs N., et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999, 42:963-970.
38. Charles P., Elliott M.J., Davis D., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 1999, 163:1521-1528.
39. Chomarat P., Vannier E., Dechanet J., et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J. Immunol. 1995, 154:1432-1439.
40. Chu C.Q., Field M., Feldmann M., Maini R.N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991, 34:1125-1132.
41. Chu C.Q., Field M., Abney E., et al. Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin. Exp. Immunol. 1991, 86:380-386.
42. Cohen S.B., Katsikis P.D., Chu C.Q., et al. High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum. 1995, 38:946-952.
43. Cope A.P., Aderka D., Doherty M., et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992, 35:1160-1169.
44. Cowell S., Knauper V., Stewart M.L., et al. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem. J. 1998, 331:453-458.
45. Cush J.J., Splawski J.B., Thomas R., et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:96-104.
46. Cutolo M., Wilder R.L. Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseases. Rheum. Dis. Clin. North Am. 2000, 26:825-839.
47. Davis D., Charles P.J., Potter A., et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br. J. Rheumatol. 1997, 36:950-956.
48. Dayan C.M., Londei M., Corcoran A.E., et al. Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc. Natl Acad. Sci. USA 1991, 88:7415-7419.
49. Dean J.L., Brook M., Clark A.R., Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J. Biol. Chem. 1999, 274:264-269.
50. Dean J.L., Wait R., Mahtani K.R., et al. The 3’ untranslated region of tumor necrosis factor alpha mRNA is a target of the mRNA-stabilizing factor HuR. Mol. Cell. Biol. 2001, 21:721-730.
51. De Graeff-Meeder E.R., van der Zee R., Rijkers G.T., et al. Recognition of human 60 kD heat shock protein by mononuclear cells from patients with juvenile chronic arthritis. Lancet 1991, 337:1368-1372.
52. D’Haens G., Van Deventer S., Van Hogezand R., et al. Endoscopic and histological healing with infliximab anti-tunor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 1999, 116:1029-1034.
53. Deleuran B.W., Chu C.Q., Field M., et al. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br. J. Rheumatol. 1992, 31:801-809.
54. Derkx B., Taminiau J., Radema S., et al. Tumour necrosis factor antibody treatment in Crohn’s disease. Lancet 1993, 342:173-174.
55. de Waal Malefyt R., Abrams J., Bennett B., et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 1991, 174:1209-1220.
56. Di Giovine F.S., Nuki G., Duff G.W. Tumour necrosis factor in synovial exudates. Ann. Rheum. Dis. 1988, 47:768-772.
57. Drexhage H.A., Bottazzo G.F., Bitensky L., et al. Thyroid growth-blocking antibodies in primary myxoedema. Nature 1981, 289:594-596.
58. Eguchi K. Apoptosis in autoimmune diseases. Intern. Med. 2001, 40:275-284.
59. Elliott M.J., Maini R.N., Feldmann M., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993, 36:1681-1690.
60. Elliott M.J., Maini R.N., Feldmann M., et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344:1125-1127.
61. Elliott M.J., Maini R.N., Feldmann M., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
62. Evans C.H., Robbins P.D., Ghivizzani S.C., et al. Results from the first human clinical trial of gene therapy for arthritis. Arthritis Rheum. 1999, 42:170. (Abstr.).
63. Fava R.A., Olsen N.J., Postlethwaite A.E., et al. Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia. J. Exp. Med. 1991, 173:1121-1132.
64. Fava R.A., Olsen N.J., Spencer-Green G., et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. 1994, 180:341-346.
65. Fedorak R.N., Gangl A., Elson C.O., et al. Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild-to-moderate active Crohn’s diseases (STAMM-CD). Gastroenterology 1998, 114:G3993. (Abstr.).
66. Feldmann M., Brennan F.M., Maini R.N. Rheumatoid arthritis. Cell 1996, 85:307-310.
67. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14:397-440.
68. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 2001, 19:163-196.
69. Fell H.B., Jubb R.W. The effect of synovial tissue on the breakdown of articular cartilage in organ culture. Arthritis Rheum. 1977, 20:1359-1371.
70. Field M., Chu C., Feldmann M., Maini R.N. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol Int. 1991, 11:45-50.
71. Fielder M., Pirt S.J., Tarpey I., et al. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. FEBS Lett. 1995, 369:243-248.
72. Fini M.E., Cook J.R., Mohan R. Proteolytic mechanisms in corneal ulceration and repair. Arch. Dermatol. Res. 1998, 290(Suppl):12-23.
73. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
74. Firestein G.S., Xu W.D., Townsend K., et al. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J. Exp. Med. 1988, 168:1573-1586.
75. Firestein G.S., Alvaro-Gracia J.M., Maki R., Alvaro-Garcia J.M. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 1990, 144:3347-3353.
76. Firestein G.S., Berger A.E., Tracey D.E., et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J. Immunol. 1992, 149:1054-1062.
77. Foey A.D., Parry S.L., Williams L.M., et al. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J. Immunol. 1998, 160:920-928.
78. Foxwell B., Browne K., Bondeson J., et al. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc. Natl Acad. Sci. USA 1998, 95:8211-8215.
79. Gery I., Streilein J.W. Autoimmunity in the eye and its regulation. Curr. Opin. Immunol. 1994, 6:938-945.
80. Goddard D.H., Grossman S.L., Moore M.E. Autocrine regulation of rheumatoid arthritis synovial cell growth in vitro. Cytokine 1990, 2:149-155.
81. Goddard D.H., Grossman S.L., Williams W.V., et al. Regulation of synovial cell growth. Coexpression of transforming growth factor beta and basic fibroblast growth factor by cultured synovial cells. Arthritis Rheum. 1992, 35:1296-1303.
82. Goldfeld A.E., Strominger J.L., Doyle C. Human tumor necrosis factor alpha gene regulation in phorbol ester stimulated T and B cell lines. J. Exp. Med. 1991, 174:73-81.
83. Gowen M., Wood D.D., Ihrie E.J., et al. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 1983, 306:378-380.
84. Grubeck-Loebenstein B. The role of cytokines in thyroid health and disease. Cytokines in Autoimmunity 1996, 101-120. R.G. Landes Company, London. F.M. Brennan, M. Feldmann (Eds.).
85. Grubeck-Loebenstein B., Buchan G., Chantry D., et al. Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 alpha and interleukin-6. Clin. Exp. Immunol. 1989, 77:324-330.
86. Gueydan C., Droogmans L., Chalon P., et al. Identification of TIAR as a protein binding to the translational regulatory AU-rich element of tumor necrosis factor alpha mRNA. J. Biol. Chem. 1999, 274:2322-2326.
87. Hachicha M., Rathanaswami P., Schall T.J., McColl S.R. Production of monocyte chemotactic protein-1 in human type B synoviocytes. Synergistic effect of tumor necrosis factor alpha and interferon-gamma. Arthritis Rheum. 1993, 36:26-34.
88. Han J., Beutler B. The essential role of the UA-rich sequence in endotoxin-induced cachectin/TNF synthesis. Eur. Cytokine. Netw. 1990, 1:71-75.
89. Han J., Jiang Y., Li Z., Kravchenko V.V., Ulevitch R.J. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 1997, 386:296-299.
90. Han Z., Boyle D.L., Chang L., et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 2001, 108:73-81.
91. Hanahan D. Peripheral-antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunity. Curr. Opin. Immunol. 1998, 10:656-662.
92. Haworth C., Brennan F.M., Chantry D., et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur. J. Immunol. 1991, 21:2575-2579.
93. Helle M., Boeije L., de Groot E., et al. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J. Immunol. Meth. 1991, 138:47-56.
94. Hermann J.A., Hall M.A., Maini R.N. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum. 1998, 41:1388-1397.
95. Hirano T., Matsuda T., Turner M., et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. 1988, 18:1797-1801.
96. Hopkins S.J., Meager A. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin. Exp. Immunol. 1988, 73:88-92.
97. Hopkins S.J., Humphreys M., Jayson M.I. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin. Exp. Immunol. 1988, 72:422-427.
98. Horwitz M.S., Bradley L.M., Harbertson J., et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat. Med. 1998, 4:781-785.
99. Hosaka S., Akahoshi T., Wada C., Kondo H. Expression of the chemokine superfamily in rheumatoid arthritis. Clin. Exp. Immunol. 1994, 97:451-457.
100. Houssiau F.A., Devogelaer J.P., Van Damme J., et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988, 31:784-788.
101. Isomaki P., Luukkainen R., Toivanen P., Punnonen J. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1996, 39:1693-1702.
102. Janeway C.A.J., Travers P. Immunobiology: The Immune System in Health and Disease 1997, Current Biology Ltd, Churchill Livingstone and Garland Publishing Inc., New York. 3rd Edn.
103. Jiang Y., Genant H.K., Watt I., et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000, 43:1001-1009.
104. Jones D.B., Coulson A.F., Duff G.W. Sequence homologies between hsp60 and autoantigens. Immunol. Today 1993, 14:115-118.
105. Joyce D.A., Gibbons D.P., Green P., et al. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur. J. Immunol. 1994, 24:2699-2705.
106. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 1995, 270:16483-16486.
107. Katsikis P.D., Chu C.Q., Brennan F.M., et al. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J. Exp. Med. 1994, 179:1517-1527.
108. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001, 345:1098-1104.
109. Keffer J., Probert L., Cazlaris H., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10:4025-4031.
110. Kelly A., Powis S.H., Glynne R., et al. Second proteasome-related gene in the human MHC class II region. Nature 1991, 353:667-668.
111. Kirkham B., Portek I., Lenarcyzk A., et al. Interleukin 17 mRNA expression in rheumatoid and psoriatic arthritis synovial membrane. Arthritis Rheum. 1997, 40:1006.
112. Knauper V., Cowell S., Smith B., et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J. Biol. Chem. 1997, 272:7608-7616.
113. Knight D.M., Trinh H., Le J., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 1993, 30:1443-1453.
114. Koch A.E., Kunkel S.L., Burrows J.C.I. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J. Immunol. 1991, 147:2187-2195.
115. Koch A.E., Kunkel S.L., Harlow L.A., et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest. 1992, 90:772-779.
116. Koch A.E., Kunkel S.L., Harlow L.A., et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J. Clin. Invest. 1994, 94:1012-1018.
117. Koch A.E., Kunkel S.L., Harlow L.A., et al. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J. Clin. Invest. 1994, 93:921-928.
118. Koch A.E., Harlow L.A., Haines G.K., et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 1994, 152:4149-4156.
119. Kolble K., Reid K.B. Genetic deficiencies of the complement system and association with disease-early components. Int. Rev. Immunol. 1993, 10:17-36.
120. Kontoyiannis D., Pasparakis M., Pizarro T.T., et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
121. Lafyatis R., Thompson N.L., Remmers E.F., et al. Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization. J. Immunol. 1989, 143:1142-1148.
122. Lai W.S., Carballo E., Strum J.R., et al. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol. Cell. Biol. 1999, 19:4311-4323.
123. Lee J.C., Laydon J.T., McDonnell P.C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372:739-746.
124. Lennon V.A., Lambert E.H. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 1980, 285:238-240.
125. Levine T.D., Gao F., King P.H., et al. Hel-N1: an autoimmune RNA-binding protein with specificity for 3’ uridylate-rich untranslated regions of growth factor mRNAs. Mol. Cell. Biol. 1993, 13:3494-3504.
126. Lin T.A., Kong X., Haystead T.A., et al. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science 1994, 266:653-656.
127. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 2000, 343:1594-1602.
128. Llorente L., Richaud-Patin Y., Fior R., et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren’s syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum. 1994, 37:1647-1655.
129. Londei M., Lamb J.R., Bottazzo G.F., Feldmann M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 1984, 312:639-641.
130. Londei M., Bottazzo G.F., Feldmann M. Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science 1985, 228:85-89.
131. Lorenz H.M., Antoni C., Valerius T., et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J. Immunol. 1996, 156:1646-1653.
132. Lotz M., Kekow J., Carson D.A. Transforming growth factor-beta and cellular immune responses in synovial fluids. J. Immunol. 1990, 144:4189-4194.
133. Lotz M., Moats T., Villiger P.M. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. J. Clin. Invest. 1992, 90:888-896.
134. Lovell D.J., Giannini E.H., Reiff A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 2000, 342:763-769.
135. Mahtani K.R., Brook M., Dean J.L., et al. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol. Cell. Biol. 2001, 21:6461-6469.
136. Maini R.N., Paulus H., Breedveld F.C., et al. rhuIL-10 in subjects with active rheumatoid arthritis (RA): a Phase I and cytokine response study. Arthritis Rheum. 1997, 40:S224. (Abstr.).
137. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998, 41:1552-1563.
138. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
139. Marino M.W., Dunn A., Grail D., et al. Characterization of tumor necrosis factor-deficient mice. Proc. Natl Acad. Sci. USA 1997, 94:8093-8098.
140. Marok R., Winyard P.G., Coumbe A., et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum. 1996, 39:583-591.
141. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990, 6:121-125.
142. McCaffrey P.G., Goldfeld A.E., Rao A. The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription. J. Biol. Chem. 1994, 269:30445-30450.
143. McInnes I.B., al-Mughales J., Field M., et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 1996, 2:175-182.
144. McInnes I.B., Illei G.G., Danning C.L., et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J. Immunol. 2001, 167:4075-4082.
145. McLay L.M., Halley F., Souness J.E., et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg. Med. Chem. 2001, 9:537-554.
146. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390.
147. Miossec P., Naviliat M., Dupuy d’Angeac A., et al. Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum. 1990, 33:1180-1187.
148. Monteleone G., Biancone L., Marasco R., et al. Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology 1997, 112:1169-1178.
149. Moreland L.W., Chase W., Fife R., et al. Phase I/II study evaluating the safety and potential efficacy of recombinant interleukin-11 in patients with refractory rheumatoid arthritis. Arthritis Rheum. 1999, 42:224.
150. Morita Y., Yamamura M., Nishida K., et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum. 1998, 41:306-314.
151. Mullin G.E., Lazenby A.J., Harris M.L., et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn’s disease but not ulcerative colitis. Gastroenterology 1992, 102:1620-1627.
152. Myer V.E., Fan X.C., Steitz J.A. Identification of HuR as a protein implicated in AUUUA-mediated mRNA decay. EMBO J. 1997, 16:2130-2139.
153. Nasution A.R., Mardjuadi A., Kunmartini S., et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J. Rheumatol. 1997, 24:1111-1114.
154. Noguchi M., Hiwatashi N., Liu Z., Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998, 43:203-209.
155. O’Garra A., Steinman L., Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr. Opin. Immunol. 1997, 9:872-883.
156. Okamoto H., Yamamura M., Morita Y., et al. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997, 40:1096-1105.
157. Oldstone M.B. Virus-induced autoimmunity: molecular mimicry as a route to autoimmune disease. J. Autoimmun. 1989, 2(Suppl.):187-194.
158. Oppenheim J.J., Feldmann M. Cytokine Reference. A Compedium of Cytokines and Other Mediators of Host Defense, volume I: Ligands 2001, Academic Press, London.
159. Paleolog E.M., Hunt M., Elliott M.J., et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. 1996, 39:1082-1091.
160. Paleolog E.M., Young S., Stark A.C., et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998, 41:1258-1265.
161. Piguet P.F., Grau G.E., Vesin C., et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992, 77:510-514.
162. Podleski W.K. Cytotoxic lymphocytes in Hashimoto’s thyroiditis. Clin. Exp. Immunol. 1972, 11:543-548.
163. Quaratino S., Feldmann M., Dayan C.M., et al. Human self-reactive T cell clones expressing identical T cell rexeptor beta chains differ in their ability to recognize a cryptic self-epitope. J. Exp. Med. 1996, 183:349-358.
164. Quinones S., Buttice G., Kurkinen M. Promoter elements in the transcriptional activation of the human stromelysin-1 gene by the inflammatory cytokine, interleukin 1. Biochem. J. 1994, 302:471-477.
165. Rathanaswami P., Hachicha M., Sadick M., et al. Expression of the cytokine RANTES in human rheumatoid synoial fibroblats. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J. Biol. Chem. 1993, 268:5834-5839.
166. Ravetch J.V., Clynes R.A. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 1998, 16:421-432.
167. Ray C.G., Palmer J.P., Crossley J.R., Williams R.H. Coxsackie B virus antibody responses in juvenile-onset diabetes mellitus. Clin. Endocrinol. (Oxf) 1980, 12:375-378.
168. Remmers E.F., Lafyatis R., Kumkumian G.K., et al. Cytokines and growth regulation of synoviocytes from patients with rheumatoid arthritis and rats with streptococcal cell wall arthritis. Growth Factors 1990, 2:179-188.
169. Remmers E.F., Sano H., Lafyatis R., et al. Production of platelet derived growth factor B chain (PDGF-B/c-sis) mRNA and immunoreactive PDGF B-like polypeptide by rheumatoid synovium: coexpression with heparin binding acidic fibroblast growth factor-1. J. Rheumatol. 1991, 18:7-13.
170. Ridley S.H., Dean J.L., Sarsfield S.J., et al. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett. 1998, 439:75-80.
171. Roux-Lombard P., Modoux C., Vischer T., et al. Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells. J. Rheumatol. 1992, 19:517-523.
172. Rutault K., Hazzalin C.A., Mahadevan L.C. Combination of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts. J. Biol. Chem. 2001, 276:6666-6674.
173. Rutgeerts P., D’Haens G., Van Deventer S.J. Retreatment with anti-TNFa chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn’s disease. Gastroenterology 1997, 112:a1078. (Abstr.).
174. Rutgeerts P., D’Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999, 117:761-769.
175. Saklatvala J., Sarsfiled S.J., Townsend Y. Pig interleukin 1. Purification of two immunologically differenti leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J. Exp. Med. 1985, 162:1208-1222.
176. Sands B.E., Bank S., Sninsky C.A., et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn’s disease. Gastroenterology 1999, 117:58-64.
177. Sano H., Forough R., Maier J.A., et al. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J. Cell. Biol. 1990, 110:1417-1426.
178. Sano H., Engleka K., Mathern P., et al. Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. J. Clin. Invest. 1993, 91:553-565.
179. Sarvetnick N., Shizuru J., Liggitt D., et al. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 1990, 346:844-847.
180. Saxne T., Palladino M.A., Heinegard D., et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 1988, 31:1041-1045.
181. Schreiber A.D., Frank M.M. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J. Clin. Invest. 1972, 51:575-582.
182. Schreiber S., Heinig T., Thiele H.G., Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995, 108:1434-1444.
183. Shahani S.K., Hattikudur N.S. Immunological consequences of vasectomy. Arch. Androl. 1981, 7:193-199.
184. Shakhov A.N., Collart M.A., Vassalli P., et al. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J. Exp. Med. 1990, 171:35-47.
185. Silman A.J., MacGregor A.J., Thomson W., et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br. J. Rheumatol. 1993, 32:903-907.
186. Singh V.K., Mehrotra S., Agarwal S.S. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res. 1999, 20:147-161.
187. Sioud M., Mellbye O., Forre O. Analysis of the NF-kappa B p65 subunit, Fas antigen, Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA. Clin. Exp. Rheumatol. 1998, 16:125-134.
188. Skopouli F.N., Moutsopoulos H.M. Cytokines in Sjogren’s syndrome. Cytokines in Autoimmunity 1996, 121-136. R.G. Landes Company, London. F.M. Brennan, M. Feldmann (Eds.).
189. Smolen J.S., Graninger W.B., Studnicka-Benke A., Steiner G. Cytokines in systemic lupus erythematosus. Cytokines in Autoimmunity 1996, 137-152. R.G. Landes Company, London. F.M. Brennan, M. Feldmann (Eds.).
190. Swantek J.L., Cobb M.H., Geppert T.D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol. Cell. Biol. 1997, 17:6274-6282.
191. Tak P.P., Taylor P.C., Breedveld F.C., et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1077-1081.
192. Taki H., Sugiyama E., Mino T., et al. Differential inhibitory effects of indomethacin, dexamethasone, and interferon-gamma (IFN-gamma) on IL-11 production by rheumatoid synovial cells. Clin. Exp. Immunol. 1998, 112:133-138.
193. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med. 1997, 337:1029-1035.
194. Taylor P.C., Peters A.M., Paleolog E., et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000, 43:38-47.
195. Tewari M., Tuncay O.C., Milchman A., et al. Association of interleukin-1-induced, NF kappa B DNA-binding activity with collagenase gene expression in human gingival fibroblasts. Arch. Oral. Biol. 1996, 41:461-468.
196. Thompson S.J., Hitsumoto Y., Ghoraishian M., et al. Cellular and humoral reactivity pattern to the mycobacterial heat shock protein hsp65 in pristane induced arthritis susceptible and hsp65 protected DBA/1 mice. Autoimmunity 1991, 11:89-95.
197. Thorbecke G.J., Shah R., Leu C.H., et al. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 1992, 89:7375-7379.
198. Townsend A., Ohlen C., Bastin J., et al. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989, 340:443-448.
199. Tsai E.Y., Yie J., Thanos D., Goldfeld A.E. Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. Mol. Cell. Biol. 1996, 16:5232-5244.
200. Tun R.Y., Smith M.D., Lo S.S., et al. Antibodies to heat shock protein 65 kD in type 1 diabetes mellitus. Diabet. Med. 1994, 11:66-70.
201. Van den Bosch F., Kruithof E., Baeten D., et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann. Rheum. Dis. 2000, 59:428-433.
202. van der Heijde D.M. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillières Clin. Rheumatol. 1996, 10:435-453.
203. van Deventer S.J., Elson C.O., Fedorak R.N. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s disease Study Group. Gastroenterology 1997, 113:383-389.
204. van Dullemen H.M., van Deventer S.J., Hommes D.W., et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135.
205. Van Voorhis W.C., Eisen H. Fl-160. A surface antigen of Trypanosoma cruzi that mimics mammalian nervous tissue. J. Exp. Med. 1989, 169:641-652.
206. Vaux D.L., Flavell R.A. Apoptosis genes and autoimmunity. Curr. Opin. Immunol. 2000, 12:719-724.
207. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int. Immunopharmacol. 2001, 1:983-993.
208. Vilcek J. Forty years of interferon, forty years of cytokines. Cytokine Growth Factor Rev. 1997, 8:239.
209. Villiger P.M., Terkeltaub R., Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J. Immunol. 1992, 149:722-727.
210. Wang X.Z., Ron D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP Kinase. Science 1996, 272:1347-1349.
211. Waring P.M., Carroll G.J., Kandiah D.A., et al. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1993, 36:911-915.
212. Waskiewicz A.J., Flynn A., Proud C.G., Cooper J.A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 1997, 16:1909-1920.
213. Wasylyk B., Hagman J., Gutierrez-Hartmann A. Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem. Sci. 1998, 23:213-216.
214. Watt I., Cobby M. Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment. Semin. Arthritis Rheum. 2001, 30:21-25.
215. Weetman A.P., McGregor A.M. Autoimmune thyroid disease: further developments in our understanding. Endocr. Rev. 1994, 15:788-830.
216. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 1999, 340:253-259.
217. Wekerle H., Bradl M., Linington C., et al. The shaping of the brain-specific T lymphocyte repertoire in the thymus. Immunol Rev. 1996, 149:231-243.
218. Whitacre C.C. Sex differences in autoimmune disease. Nat. Immunol. 2001, 2:777-780.
219. Williams R.O., Feldmann M., Maini R.N. Antitumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 1992, 89:9784-9788.
220. Williams R.O., Mason L.J., Feldmann M., Maini R.N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl Acad. Sci. USA 1994, 91:2762-2766.
221. Williams R.O., Malfait A.M., Butler D.M., et al. Combination therapy with DMARDs and biological agents in collagen-induced arthritis. Clin. Exp. Rheumatol. 1999, 17:S115-S120.
222. Wood N.C., Dickens E., Symons J.A., Duff G.W. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Clin. Immunol. Immunopathol. 1992, 62:295-300.
223. Wooley P.H., Dutcher J., Widmer M.B., Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 1993, 151:6602-6607.
224. Wordsworth P., Bell J. Polygenic susceptibility in rheumatoid arthritis. Ann. Rheum. Dis. 1991, 50:343-346.
225. Xu W.D., Firestein G.S., Taetle R., et al. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J. Clin. Invest. 1989, 83:876-882.
226. Yamamura M., Kawashima M., Morita Y., et al. Increased production of interleukin-18 in synovium from patients with rheumatoid arthritis. Arthritis Rheum. 1997, 40:1459.
227. Yoshizaki K., Nishimoto N., Mihara M., Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Semin. Immunopathol. 1998, 20:247-259.
228. Zhang W., Wagner B.J., Ehrenman K., et al. Purification, characterization, and cDNA cloning of an AU-rich element RNA-binding protein, AUF1. Mol. Cell. Biol. 1993, 13:7652-7665.
229. Zhao M., New L., Kravchenko V.V., et al. Regulation of the MEF2 family of transcription factors by p38. Mol. Cell. Biol. 1999, 19:21-30.